Anuh Pharma quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	194	186	+3.9%
EBITDA	16.3	10.3	+58.3%
EBITDA margin	8.4%	5.5%	+2.9 pts
Profit before tax	16.9	11.0	+54.6%
Net profit	11.4	8.3	+37.6%
EPS	₹1.14	₹1.66	−31.3%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024

Expenses
	194	202	197	186	186	198	160
	3.1	−1.3	4.1	1.0	3.4	1.4	0.9
	197	201	201	187	190	200	160
	160	141	114	132	124	138	119
	4.1	2.8	31.5	18.4	26.5	10.9	14.5
	−15.8	7.7	5.5	−5.4	2.2	−0.4	−12.7
	7.4	6.3	6.9	6.7	6.3	6.8	5.5
	0.0	0.1	0.1	0.1	0.2	0.0	0.3
	2.4	3.0	3.0	2.9	2.5	2.8	2.2
	21.9	24.7	22.2	22.7	17.3	24.2	18.7
	180	185	183	177	179	182	147
	16.3	19.9	16.8	11.9	10.3	18.7	14.8
	13.9	16.9	13.8	9.0	7.8	15.9	12.6
Profit
	16.9	15.5	17.8	9.9	11.0	17.3	13.3
	16.9	15.5	17.8	9.9	11.0	17.3	13.3
	4.1	4.8	5.0	2.8	2.5	5.4	3.2
	1.4	−0.9	−0.6	−0.5	0.2	−0.6	−0.3
	5.5	3.8	4.4	2.3	2.7	4.8	2.9
	11.4	11.7	13.5	7.6	8.3	12.5	10.3
	11.4	11.7	13.5	7.6	8.3	12.5	10.3
	−0.0	−0.3	0.5	0.1	−0.1	0.1	0.0
	11.4	11.4	13.9	7.7	8.2	12.6	10.4
Per share
	₹1.14	₹1.17	₹1.34	₹0.76	₹1.66	₹2.49	₹2.06
	₹1.14	₹1.17	₹1.34	₹0.76	₹1.66	₹2.49	₹2.06
Other comprehensive income — detail
	−0.0	−0.3	0.5	0.1	−0.1	0.1	—
	−0.0	−0.4	0.6	0.1	−0.1	0.1	0.0
	−0.0	−0.1	0.2	0.0	−0.0	0.0	—
	—	—	—	—	—	—	0.0
Per share — as-filed variants
	₹1.14	₹1.17	₹1.34	₹0.76	₹1.66	₹2.49	₹2.06
	₹1.14	₹1.17	₹1.34	₹0.76	₹1.66	₹2.49	₹2.06
Regulatory disclosures — filed alongside, not part of the P&L
	—	44.8	—	28.3	—	24.8	—
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	45.5	50.9	45.9	41.3	33.9	49.7	39.0
	23.5%	25.2%	23.3%	22.2%	18.2%	25.1%	24.5%
Adjusted (ex-exceptional items) — derived
	16.9	15.5	17.8	9.9	11.0	17.3	13.3
	11.4	11.7	13.5	7.6	8.3	12.5	10.3
	₹1.14	₹1.17	₹1.34	₹0.76	₹1.66	₹2.49	₹2.06

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

ANUHPHR₹79.61

Anuh Pharma Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersAHCL WANBURY ZIMLAB BAJAJHCARE THEMISMED LINCOLN VALIANTLAB SIGACHIMcap ₹798 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	159.5	198.1	186.5	185.9	197.2	202.1	193.8
Other Income	0.9	1.4	3.4	1.0	4.1	-1.3	3.1
Total Income	160.5	199.5	189.9	186.9	201.3	200.9	196.9
Expenses
+ Cost of Materials Consumed	118.7	137.9	123.9	131.5	114.3	140.7	160.0
+ Purchases of Stock-in-Trade	14.5	10.9	26.5	18.4	31.5	2.8	4.1
+ Changes in Inventories	-12.7	-0.4	2.2	-5.4	5.5	7.7	-15.8
+ Employee Benefit Expense	5.5	6.8	6.3	6.7	6.9	6.3	7.4
+ Finance Costs	0.3	0.0	0.2	0.1	0.1	0.1	0.0
+ Depreciation & Amortisation	2.2	2.8	2.5	2.9	3.0	3.0	2.4
+ Other Expenses	18.7	24.2	17.3	22.7	22.2	24.7	21.9
Total Expenses	147.2	182.3	178.9	176.9	183.5	185.3	180.0
EBITDA	14.8	18.7	10.3	11.9	16.8	19.9	16.3
EBIT	12.6	15.9	7.8	9.0	13.8	16.9	13.9
Profit
PBT before Exceptional Items	13.3	17.3	11.0	9.9	17.8	15.5	16.9
Pretax Income	13.3	17.3	11.0	9.9	17.8	15.5	16.9
+ Current Tax	3.2	5.4	2.5	2.8	5.0	4.8	4.1
+ Deferred Tax	-0.3	-0.6	0.2	-0.5	-0.6	-0.9	1.4
Tax Expense	2.9	4.8	2.7	2.3	4.4	3.8	5.5
Net Income	10.3	12.5	8.3	7.6	13.5	11.7	11.4
+ Net Income — Continuing Ops	10.3	12.5	8.3	7.6	13.5	11.7	11.4
+ Other Comprehensive Income	0.0	0.1	-0.1	0.1	0.5	-0.3	-0.0
Total Comprehensive Income	10.4	12.6	8.2	7.7	13.9	11.4	11.4
Per Share
Basic EPS	2.06	2.49	1.66	0.76	1.34	1.17	1.14
Diluted EPS	2.06	2.49	1.66	0.76	1.34	1.17	1.14
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	0.1	-0.1	0.1	0.5	-0.3	-0.0
+ Items NOT to be Reclassified to P&L	0.0	0.1	-0.1	0.1	0.6	-0.4	-0.0
+ Tax on Items NOT to be Reclassified	—	0.0	-0.0	0.0	0.2	-0.1	-0.0
+ Tax on Items NOT to be Reclassified — alt tag	0.0	—	—	—	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	2.06	2.49	1.66	0.76	1.34	1.17	1.14
Diluted EPS — Continuing Operations	2.06	2.49	1.66	0.76	1.34	1.17	1.14
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period	—	24.8	—	28.3	—	44.8	—
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	39.0	49.7	33.9	41.3	45.9	50.9	45.5
Gross Margin %	24.47	25.07	18.16	22.24	23.28	25.18	23.48
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	13.3	17.3	11.0	9.9	17.8	15.5	16.9
Net Income Adj (tax-effected)	10.3	12.5	8.3	7.6	13.5	11.7	11.4
EPS Adj	2.06	2.49	1.66	0.76	1.34	1.17	1.14
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Paid Up Equity Capital	25.1	25.1	25.1	50.1	50.1	50.1	50.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Anuh Pharma Q2 FY27 results date

Anuh Pharma (NSE: ANUHPHR) will announce its Q2 FY27 results (July–September 2026) on Friday, 30 October 2026, according to the board-meeting notice it filed on 26 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹11.4 crore, up 37.6% from ₹8.3 crore in Q1 FY26 and down 2.2% from ₹11.7 crore in Q4 FY26. Revenue from operations was ₹194 crore, up 3.9% year on year and down 4.1% from the previous quarter.

Board-meeting notice filed: 26 October 2026
Q2 FY26 results (a year earlier): 7 November 2025
Q1 FY27 results (the latest): 7 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 30 October 2026Friday · notice filed 26 Oct
Q1 FY27 net profit: ₹11.4 Cr+37.6% vs Q1 FY26−2.2% vs Q4 FY26
Q1 FY27 revenue: ₹194 Cr+3.9% vs Q1 FY26−4.1% vs Q4 FY26
Q1 FY27 operating margin: 7.1%+3.0 pts vs Q1 FY26−1.2 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹7.6 CrRevenue ₹186 Cr
Q1 FY27 EPS (basic): ₹1.14

Questions

When will Anuh Pharma announce its Q2 FY27 results?

On 30 October 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 26 October 2026). Last year it reported Q2 FY26 on 7 November 2025.

What will Anuh Pharma's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹7.6 crore and revenue from operations ₹186 crore. The latest quarter, Q1 FY27, had a net profit of ₹11.4 crore and revenue of ₹194 crore.

What were Anuh Pharma's Q1 FY27 results?

Consolidated net profit was ₹11.4 crore, up 37.6% from ₹8.3 crore in Q1 FY26 and down 2.2% from ₹11.7 crore in Q4 FY26. Revenue from operations was ₹194 crore, up 3.9% year on year and down 4.1% from the previous quarter.

How has Anuh Pharma's profit changed over the last four quarters?

Net profit by quarter: ₹7.6 crore in Q2 FY26, ₹13.5 crore in Q3 FY26, ₹11.7 crore in Q4 FY26 and ₹11.4 crore in Q1 FY27. That is ₹44.2 crore over the four quarters. Revenue from operations: ₹186 crore, ₹197 crore, ₹202 crore and ₹194 crore.

What was Anuh Pharma's net profit in FY26?

Consolidated net profit was ₹41 crore in FY26 (April 2025–March 2026), down 13.3% from ₹47.4 crore in FY25.

What was Anuh Pharma's revenue in FY26?

Revenue from operations was ₹772 crore in FY26 (April 2025–March 2026), up 16.7% from ₹662 crore in FY25.

Where do these Anuh Pharma figures come from?

From Anuh Pharma's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.